SCHEMBL1506212

SCHEMBL1506212

COC(=O)Cc1cc(Nc2cccc(Cl)c2F)nn1-c1ccnc(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 4/20 0.43
▸ P2RX7 Q99572 1/20 0.40
▸ IDO1 P14902 1/20 0.38
▸ CSF1R P07333 1/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ EGFR P00533 8/20 0.36
▸ ERBB2 P04626 4/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ GAK O14976 1/20 0.36
▸ RIPK2 O43353 1/20 0.36
▸ LYN P07948 1/20 0.36
▸ RET P07949 1/20 0.36
▸ EPHA1 P21709 1/20 0.36
▸ ERBB3 P21860 1/20 0.36
▸ EPHA2 P29317 1/20 0.36
▸ EPHB2 P29323 1/20 0.36
▸ EPHA5 P54756 1/20 0.36
▸ EPHB4 P54760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506203 0.91 RIPK1 (0.44) RIPK1CSF1REGFRHDAC3HDAC1
SCHEMBL1506304 0.89 P2RX7 (0.42) RIPK1P2RX7IDO1MAPK1EGFR
SCHEMBL1506082 0.87 P2RX7 (0.45) RIPK1P2RX7IDO1MAPK1ERBB2
SCHEMBL1506079 0.86 IDO1 (0.41) RIPK1P2RX7IDO1MAPK1EGFR
SCHEMBL1506117 0.86 RIPK1 (0.41) RIPK1P2RX7IDO1MAPK1HDAC3
SCHEMBL10010359 0.86 P2RX7 (0.40) RIPK1P2RX7IDO1MAPK1EGFR
SCHEMBL1506129 0.84 P2RX7 (0.42) RIPK1P2RX7IDO1MAPK1EGFR
SCHEMBL10008796 0.84 MAPK1 (0.39) RIPK1P2RX7MAPK1EGFRERBB2
SCHEMBL1506211 0.84 IDO1 (0.40) RIPK1P2RX7IDO1MAPK1EGFR
SCHEMBL10009079 0.84 ERBB2 (0.39) RIPK1P2RX7IDO1MAPK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 RIPK1 2211/4885P2RX7 43/4885IDO1 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback